Philippe Berthon, CEO
Prior to joining Tridek One, Philippe was CEO of Aurgalys, a corporate finance advisory company he founded in 2008. Aurgalys was sold to Genesta in June 2018. Previously, he was CEO of Vaxon-Biotech, a company that developed anti-cancer immunotherapeutic products. Philippe also founded and led UroGene as a spin-off of his university research laboratory, a company dedicated to urological diseases, including cancer and incontinence. UroGene was sold to the Pierre Fabre Group in early 2005. Prior to these positions, Dr. Berthon was co-founder and director of the Onco-urology Research Laboratory (UPRES 3104) at the Saint-Louis Hospital in Paris, senior postdoc fellow at the Cancer Research Unit, University of York, UK, and Research fellow at Pierre and Marie Curie University. Dr. Berthon has co-authored more than 50 international peer-reviewed publications, obtained his Ph.D. in Reproductive Physiology from Paris Pierre and Marie Curie University, and is a graduate of the Challenge + Business and Administration program at HEC School of Management in Jouy-en-Josas, France. Philippe is also registered financial analyst with the Société Française des Analystes Financiers (SFAF) and an approved Euronext Listing Sponsor.
Regis Olivier, CFO
Régis brings more than 25 years of experience in the areas of finance, structuring and management of health technology companies. Prior to joining Tridek One, Regis was CEO of Axess Vision Technology, a company dedicated to the development of single-use medical endoscopes where he led the launch of new products and successfully completed new financing rounds. Also former CFO of Echosens, a medical technology company specializing in the non-invasive detection of liver disease, he completed the structuring and sale of the company in 2011. Previously, he held several positions as a financial analyst and financial controller in several industrial companies. Mr. Olivier holds a Master’s degree in Management and Finance from EDC Paris.
Jorge Kirilovsky, CSO
Jorge is recognized as an international expert in the field of drug discovery. A former vice president and head of GSK’s drug discovery center in France, Jorge led a group of more than 100 biologists, chemists, pharmacokinetists and clinicians working together to identify new drug candidates for development. The discovery of Tadalafil (Cialis™) for the treatment of erectile dysfunction and the first epigenetic drug to achieve clinical development are among the main contributions of his team. Dr Kirilovsky has also participated in the identification and selection of about twenty drug candidates in the fields of immuno-inflammation, cardiovascular diseases and oncology. Jorge is currently a member of the Health Expert Committee of BPI Large Ventures, the SATT Paris-Saclay Investment Committee and the Medicene Paris Project Appraisal Committee. In addition, he supports Yukin Therapeutics. Jorge Kirilovsky received his Ph.D. in biochemistry from the Hebrew University of Jerusalem and completed postdoctoral training in molecular neurobiology at the Institut Pasteur in Paris.
Delphine Joyeux, CDO
Delphine has developed her regulatory affairs expertise in Europe and the United States at all stages of product development. She has been successful in filing and obtaining approval for numerous clinical trial applications, INDs, marketing approvals and new drug applications in Europe (EMA) and the United States (FDA), including Loramyc ™, Sitavig ™, Pretherax ™. Prior to joining Tridek One, Dr Joyeux was Chief Operating Officer at Minka Therapeutics and held various regulatory affairs and product development positions at Onxeo in France, Agouron-Pfizer in the United States and Servier in France. Delphine Joyeux obtained her doctorate in pharmacy from Paris-Saclay University as well as a master’s degree in international development and registration of medicinal products.